US House appropriators propose increasing the Food and Drug Administration’s funding for developing a regulatory pathway for lawful use of hemp-derived cannabidiols in non-drug products but also expect an uptick in the agency’s enforcement in the current marketplace.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?